
Ying-Yong Zhao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2509397/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	1â€Hydroxypyrene mediates renal fibrosis through aryl hydrocarbon receptor signalling pathway. British Journal of Pharmacology, 2022, 179, 103-124.	2.7	28
2	Altered lipid metabolism and serum lipids in chronic kidney disease. , 2022, , 43-60.		2
3	TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis. Frontiers in Pharmacology, 2022, 13, 860588.	1.6	31
4	Serum Metabolites Associated with Blood Pressure in Chronic Kidney Disease Patients. Metabolites, 2022, 12, 281.	1.3	1
5	Host/microbiota interactions-derived tryptophan metabolites modulate oxidative stress and inflammation via aryl hydrocarbon receptor signaling. Free Radical Biology and Medicine, 2022, 184, 30-41.	1.3	25
6	Intrarenal 1-methoxypyrene, an aryl hydrocarbon receptor agonist, mediates progressive tubulointerstitial fibrosis in mice. Acta Pharmacologica Sinica, 2022, 43, 2929-2945.	2.8	23
7	Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy. Frontiers in Pharmacology, 2022, 13, .	1.6	13
8	Aryl hydrocarbon receptor: From pathogenesis to therapeutic targets in aging-related tissue fibrosis. Ageing Research Reviews, 2022, 79, 101662.	5.0	11
9	Deciphering the cellular mechanisms underlying fibrosis-associated diseases and therapeutic avenues. Pharmacological Research, 2021, 163, 105316.	3.1	32
10	Gut microbiota-derived tryptophan metabolism mediates renal fibrosis by aryl hydrocarbon receptor signaling activation. Cellular and Molecular Life Sciences, 2021, 78, 909-922.	2.4	95
11	Polyporus Umbellatus Protects Against Renal Fibrosis by Regulating Intrarenal Fatty Acyl Metabolites. Frontiers in Pharmacology, 2021, 12, 633566.	1.6	8
12	The Dysregulation of Eicosanoids and Bile Acids Correlates with Impaired Kidney Function and Renal Fibrosis in Chronic Renal Failure. Metabolites, 2021, 11, 127.	1.3	10
13	Long non-coding RNAs: A double-edged sword in aging kidney and renal disease. Chemico-Biological Interactions, 2021, 337, 109396.	1.7	13
14	Targeting the Wnt/β-Catenin Signaling Pathway as a Potential Therapeutic Strategy in Renal Tubulointerstitial Fibrosis. Frontiers in Pharmacology, 2021, 12, 719880.	1.6	46
15	AGE/RAGE in diabetic kidney disease and ageing kidney. Free Radical Biology and Medicine, 2021, 171, 260-271.	1.3	90
16	Editorial: Applications of Herbal Medicine to Control Chronic Kidney Disease. Frontiers in Pharmacology, 2021, 12, 742407.	1.6	1
17	EditPredict: Prediction of RNA editable sites with convolutional neural network. Genomics, 2021, 113, 3864-3871.	1.3	6
18	Shenkang Injection and Its Three Anthraquinones Ameliorates Renal Fibrosis by Simultaneous Targeting IƙB/NF-ƙB and Keap1/Nrf2 Signaling Pathways. Frontiers in Pharmacology, 2021, 12, 800522.	1.6	41

#	Article	IF	CITATIONS
19	Cancer-specific expression quantitative loci are affected by expression dysregulation. Briefings in Bioinformatics, 2020, 21, 338-347.	3.2	4
20	Small molecule inhibitors of epithelialâ€mesenchymal transition for the treatment of cancer and fibrosis. Medicinal Research Reviews, 2020, 40, 54-78.	5.0	93
21	MutEx: a multifaceted gateway for exploring integrative pan-cancer genomic data. Briefings in Bioinformatics, 2020, 21, 1479-1486.	3.2	12
22	Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. RNA Biology, 2020, 17, 1666-1673.	1.5	26
23	Asiatic acid prevents renal fibrosis in UUO rats via promoting the production of 15d-PGJ2, an endogenous ligand of PPAR-γ. Acta Pharmacologica Sinica, 2020, 41, 373-382.	2.8	34
24	Machine learning distilled metabolite biomarkers for early stage renal injury. Metabolomics, 2020, 16, 4.	1.4	18
25	Expression correlation attenuates within and between key signaling pathways in chronic kidney disease. BMC Medical Genomics, 2020, 13, 134.	0.7	9
26	Poricoic acid A as a modulator of TPH-1 expression inhibits renal fibrosis <i>via</i> modulating protein stability of β-catenin and β-catenin-mediated transcription. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232096264.	1.1	17
27	Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights. Archives of Biochemistry and Biophysics, 2020, 695, 108623.	1.4	8
28	Novel poricoic acids attenuate renal fibrosis through regulating redox signalling and aryl hydrocarbon receptor activation. Phytomedicine, 2020, 79, 153323.	2.3	27
29	SMDB: pivotal somatic sequence alterations reprogramming regulatory cascades. NAR Cancer, 2020, 2, zcaa030.	1.6	8
30	Redox signaling and Alzheimer's disease: from pathomechanism insights to biomarker discovery and therapy strategy. Biomarker Research, 2020, 8, 42.	2.8	20
31	Alisol B 23-acetate attenuates CKD progression by regulating the renin–angiotensin system and gut–kidney axis. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232092002.	1.1	19
32	Non-canonical RNA-DNA differences and other human genomic features are enriched within very short tandem repeats. PLoS Computational Biology, 2020, 16, e1007968.	1.5	4
33	Identification of endogenous 1â€aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation. British Journal of Pharmacology, 2020, 177, 3415-3435.	2.7	50
34	AnnoGen: annotating genome-wide pragmatic features. Bioinformatics, 2020, 36, 2899-2901.	1.8	4
35	Wnt signaling pathway in aging-related tissue fibrosis and therapies. Ageing Research Reviews, 2020, 60, 101063.	5.0	100
36	Poricoic acid A activates AMPK to attenuate fibroblast activation and abnormal extracellular matrix remodelling in renal fibrosis. Phytomedicine, 2020, 72, 153232.	2.3	28

#	Article	IF	CITATIONS
37	Title is missing!. , 2020, 16, e1007968.		0
38	Title is missing!. , 2020, 16, e1007968.		0
39	Title is missing!. , 2020, 16, e1007968.		0
40	Title is missing!. , 2020, 16, e1007968.		0
41	Title is missing!. , 2020, 16, e1007968.		0
42	Title is missing!. , 2020, 16, e1007968.		0
43	Quality and concordance of genotyping array data of 12,064 samples from 5840 cancer patients. Genomics, 2019, 111, 950-957.	1.3	7
44	Dietary natural flavonoids treating cancer by targeting aryl hydrocarbon receptor. Critical Reviews in Toxicology, 2019, 49, 445-460.	1.9	44
45	Combined melatonin and poricoic acid A inhibits renal fibrosis through modulating the interaction of Smad3 and β-catenin pathway in AKI-to-CKD continuum. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986911.	1.1	38
46	Natural products against renin-angiotensin system for antifibrosis therapy. European Journal of Medicinal Chemistry, 2019, 179, 623-633.	2.6	30
47	Chronic kidney disease: Biomarker diagnosis to therapeutic targets. Clinica Chimica Acta, 2019, 499, 54-63.	0.5	72
48	Aryl hydrocarbon receptor activation mediates kidney disease and renal cell carcinoma. Journal of Translational Medicine, 2019, 17, 302.	1.8	42
49	Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/Axl NF κB/Nrf2 axis. Free Radical Biology and Medicine, 2019, 134, 484-497.	1.3	76
50	Small molecules from natural products targeting the Wnt/β-catenin pathway as a therapeutic strategy. Biomedicine and Pharmacotherapy, 2019, 117, 108990.	2.5	52
51	Microbiome–metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease. Cellular and Molecular Life Sciences, 2019, 76, 4961-4978.	2.4	146
52	Redox signaling in aging kidney and opportunity for therapeutic intervention through natural products. Free Radical Biology and Medicine, 2019, 141, 141-149.	1.3	29
53	The Application of Machine Learning Algorithms to Diagnose CKD Stages and Identify Critical Metabolites Features. Lecture Notes in Computer Science, 2019, , 72-83.	1.0	2
54	Activated NF-κB/Nrf2 and Wnt/β-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2317-2332.	1.8	42

#	Article	IF	CITATIONS
55	Architectures and accuracy of artificial neural network for disease classification from omics data. BMC Genomics, 2019, 20, 167.	1.2	58
56	Genomic Positional Dissection of RNA Editomes in Tumor and Normal Samples. Frontiers in Genetics, 2019, 10, 211.	1.1	19
57	Recognition of Bisecting <i>N</i> -Glycans on Intact Glycopeptides by Two Characteristic lons in Tandem Mass Spectra. Analytical Chemistry, 2019, 91, 5478-5482.	3.2	28
58	The Matrix Metalloproteinaseâ€13 Inhibitor Poricoic Acid ZI Ameliorates Renal Fibrosis by Mitigating Epithelialâ€Mesenchymal Transition. Molecular Nutrition and Food Research, 2019, 63, e1900132.	1.5	33
59	Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis. Experimental and Molecular Medicine, 2019, 51, 1-18.	3.2	90
60	Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan. Nature Communications, 2019, 10, 1476.	5.8	171
61	Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease. Journal of Translational Medicine, 2019, 17, 5.	1.8	233
62	Preparation and characterization of D. opposita Thunb polysaccharide-zinc inclusion complex and evaluation of anti-diabetic activities. International Journal of Biological Macromolecules, 2019, 121, 1029-1036.	3.6	31
63	Single-nucleotide variants in human RNA: RNA editing and beyond. Briefings in Functional Genomics, 2019, 18, 30-39.	1.3	17
64	Novel inhibitors of the cellular reninâ€angiotensin system components, poricoic acids, target Smad3 phosphorylation and Wnt/l²â€catenin pathway against renal fibrosis. British Journal of Pharmacology, 2018, 175, 2689-2708.	2.7	154
65	Submicron emulsion of cinnamaldehyde ameliorates bleomycin-induced idiopathic pulmonary fibrosis via inhibition of inflammation, oxidative stress and epithelial-mesenchymal transition. Biomedicine and Pharmacotherapy, 2018, 102, 765-771.	2.5	20
66	Novel RAS Inhibitors Poricoic Acid ZG and Poricoic Acid ZH Attenuate Renal Fibrosis via a Wnt/β-Catenin Pathway and Targeted Phosphorylation of smad3 Signaling. Journal of Agricultural and Food Chemistry, 2018, 66, 1828-1842.	2.4	115
67	Proteomics for Biomarker Identification and Clinical Application in Kidney Disease. Advances in Clinical Chemistry, 2018, 85, 91-113.	1.8	41
68	Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-β-mediated Smad3 phosphorylation. Phytomedicine, 2018, 42, 207-218.	2.3	93
69	Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment. Biomedicine and Pharmacotherapy, 2018, 101, 670-681.	2.5	250
70	Power and sample size calculations for high-throughput sequencing-based experiments. Briefings in Bioinformatics, 2018, 19, 1247-1255.	3.2	32
71	Tri-allelic heteroplasmies, DNA-RNA differences and their polynucleotide tract associations in the mitochondrial genome. Genomics, 2018, 110, 211-220.	1.3	2
72	Natural Products as a Source for Antifibrosis Therapy. Trends in Pharmacological Sciences, 2018, 39, 937-952.	4.0	162

#	Article	IF	CITATIONS
73	Biomarkers of obstructive nephropathy using a metabolomics approach in rat. Chemico-Biological Interactions, 2018, 296, 229-239.	1.7	25
74	Natural products for the prevention and treatment of kidney disease. Phytomedicine, 2018, 50, 50-60.	2.3	92
75	Rhubarb Protect Against Tubulointerstitial Fibrosis by Inhibiting TGF-β/Smad Pathway and Improving Abnormal Metabolome in Chronic Kidney Disease. Frontiers in Pharmacology, 2018, 9, 1029.	1.6	55
76	An Integrated Lipidomics and Phenotype Study Reveals Protective Effect and Biochemical Mechanism of Traditionally Used Alisma orientale Juzepzuk in Chronic Kidney Disease. Frontiers in Pharmacology, 2018, 9, 53.	1.6	43
77	The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. Genes, 2018, 9, 29.	1.0	21
78	New insights into TGF-β/Smad signaling in tissue fibrosis. Chemico-Biological Interactions, 2018, 292, 76-83.	1.7	671
79	Metabolomics highlights pharmacological bioactivity and biochemical mechanism of traditional Chinese medicine. Chemico-Biological Interactions, 2017, 273, 133-141.	1.7	194
80	Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/l̂2-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease. Redox Biology, 2017, 12, 505-521.	3.9	146
81	The link between phenotype and fatty acid metabolism in advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2017, 32, 1154-1166.	0.4	91
82	Combined Clinical Phenotype and Lipidomic Analysis Reveals the Impact of Chronic Kidney Disease on Lipid Metabolism. Journal of Proteome Research, 2017, 16, 1566-1578.	1.8	108
83	Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites. Clinical Biochemistry, 2017, 50, 1078-1086.	0.8	37
84	Estimating relative mitochondrial DNA copy number using high throughput sequencing data. Genomics, 2017, 109, 457-462.	1.3	16
85	Poricoic acid ZA, a novel RAS inhibitor, attenuates tubulo-interstitial fibrosis and podocyte injury by inhibiting TGF-β/Smad signaling pathway. Phytomedicine, 2017, 36, 243-253.	2.3	84
86	Urinary biomarker and treatment mechanism of <i>Rhizoma Alismatis</i> on hyperlipidemia. Biomedical Chromatography, 2017, 31, e3829.	0.8	37
87	Current Research on Non-Coding Ribonucleic Acid (RNA). Genes, 2017, 8, 366.	1.0	54
88	Role of RAS/Wnt/β-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy. Chemico-Biological Interactions, 2017, 273, 56-72.	1.7	91
89	Characterization of a Novel Polysaccharide-Iron(III) Complex and Its Anti-Anemia and Nonspecific Immune Regulating Activities. Mini-Reviews in Medicinal Chemistry, 2017, 17, 1677-1683.	1.1	10
90	Review of Characteristics, Pharmacology, Determination and Pharmacokinetics of Rhaponticin. Mini-Reviews in Organic Chemistry, 2017, 14, 24-34.	0.6	5

#	Article	IF	CITATIONS
91	An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure. Scientific Reports, 2016, 6, 22151.	1.6	130
92	Metabolomic application in toxicity evaluation and toxicological biomarker identification of natural product. Chemico-Biological Interactions, 2016, 252, 114-130.	1.7	74
93	Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. Redox Biology, 2016, 10, 168-178.	3.9	148
94	Metabolomic Signatures of Chronic Kidney Disease of Diverse Etiologies in the Rats and Humans. Journal of Proteome Research, 2016, 15, 3802-3812.	1.8	71
95	Traditional uses, fermentation, phytochemistry and pharmacology of Phellinus linteus: A review. Fìtoterapìâ, 2016, 113, 6-26.	1.1	95
96	Lipidomics Biomarkers of Diet-Induced Hyperlipidemia and Its Treatment with <i>Poria cocos</i> . Journal of Agricultural and Food Chemistry, 2016, 64, 969-979.	2.4	82
97	Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrology Dialysis Transplantation, 2016, 31, 737-746.	0.4	296
98	Research Progress of Natural Product Gentiopicroside - a Secoiridoid Compound. Mini-Reviews in Medicinal Chemistry, 2016, 17, 62-77.	1.1	24
99	Metabolomics Reveals Hyperlipidemic Biomarkers and Antihyperlipidemic Effect of Poria cocos. Current Metabolomics, 2016, 4, 104-115.	0.5	13
100	Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Scientific Reports, 2015, 5, 12936.	1.6	149
101	Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis. Scientific Reports, 2015, 5, 14472.	1.6	142
102	Plasma lipidomics reveal profound perturbation of glycerophospholipids, fatty acids, and sphingolipids in diet-induced hyperlipidemia. Chemico-Biological Interactions, 2015, 228, 79-87.	1.7	78
103	Lipidomics. Advances in Clinical Chemistry, 2015, 68, 153-175.	1.8	95
104	Lipidomics applications for disease biomarker discovery in mammal models. Biomarkers in Medicine, 2015, 9, 153-168.	0.6	70
105	Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS. Bioanalysis, 2015, 7, 685-700.	0.6	52
106	Urine metabolomics reveals new insights into hyperlipidemia and the therapeutic effect of rhubarb. Analytical Methods, 2015, 7, 3113-3123.	1.3	24
107	Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease. Free Radical Biology and Medicine, 2015, 86, 374-381.	1.3	39
108	The antihyperlipidemic effect of Fu-Ling-Pi is associated with abnormal fatty acid metabolism as assessed by UPLC-HDMS-based lipidomics. RSC Advances, 2015, 5, 64208-64219.	1.7	23

#	Article	IF	CITATIONS
109	Lipidomics: Novel insight into the biochemical mechanism of lipid metabolism and dysregulation-associated disease. Chemico-Biological Interactions, 2015, 240, 220-238.	1.7	107
110	A Pharmaco-Metabonomic Study on Chronic Kidney Disease and Therapeutic Effect of Ergone by UPLC-QTOF/HDMS. PLoS ONE, 2014, 9, e115467.	1.1	55
111	The proliferation, differentiation, and mineralization effects of puerarin on osteoblasts in vitro. Chinese Journal of Natural Medicines, 2014, 12, 436-442.	0.7	21
112	Lipidomics Applications for Discovering Biomarkers of Diseases in Clinical Chemistry. International Review of Cell and Molecular Biology, 2014, 313, 1-26.	1.6	101
113	Metabolomics in Dyslipidemia. Advances in Clinical Chemistry, 2014, 66, 101-119.	1.8	79
114	Quality Control of Natural Product Medicine and Nutrient Supplements 2014. Journal of Analytical Methods in Chemistry, 2014, 2014, 1-2.	0.7	2
115	Using the Doubly Charged Selected Ion Coupled with MS/MS Fragments Monitoring (DCSI-MS/MS) Mode for the Identification of Gelatin Species. Journal of Analytical Methods in Chemistry, 2014, 2014, 1-7.	0.7	8
116	UPLC–MSE application in disease biomarker discovery: The discoveries in proteomics to metabolomics. Chemico-Biological Interactions, 2014, 215, 7-16.	1.7	125
117	Metabolomics in Nephrotoxicity. Advances in Clinical Chemistry, 2014, , 69-89.	1.8	79
118	Traditional uses, phytochemistry, pharmacology, toxicology and quality control of Alisma orientale (Sam.) Juzep: A review. Journal of Ethnopharmacology, 2014, 158, 373-387.	2.0	136
119	UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry. Clinical Biochemistry, 2014, 47, 16-26.	0.8	123
120	Ultra-performance liquid chromatography–mass spectrometry as a sensitive and powerful technology in lipidomic applications. Chemico-Biological Interactions, 2014, 220, 181-192.	1.7	127
121	Diuretic and anti-diuretic activities of fractions of Alismatis rhizoma. Journal of Ethnopharmacology, 2014, 157, 114-118.	2.0	70
122	Diuretic and anti-diuretic activities of the ethanol and aqueous extracts of Alismatis rhizoma. Journal of Ethnopharmacology, 2014, 154, 386-390.	2.0	64
123	Metabolomics in nephrotoxicity. Advances in Clinical Chemistry, 2014, 65, 69-89.	1.8	26
124	Studies on the Aggregation-Induced Synchronous Emission of 1,8-Naphthalimide Derivative to Casein and Its Analytic Application. Food Analytical Methods, 2013, 6, 1253-1257.	1.3	6
125	Traditional uses, phytochemistry, pharmacology, pharmacokinetics and quality control of Polyporus umbellatus (Pers.) Fries: A review. Journal of Ethnopharmacology, 2013, 149, 35-48.	2.0	93
126	Urinary metabonomic study of the surface layer of Poria cocos as an effective treatment for chronic renal injury in rats. Journal of Ethnopharmacology, 2013, 148, 403-410.	2.0	94

#	Article	IF	CITATIONS
127	Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate. Bioorganic and Medicinal Chemistry, 2013, 21, 178-185.	1.4	8
128	Intrarenal Metabolomic Investigation of Chronic Kidney Disease and its TGF-β1 Mechanism in Induced-adenine Rats using UPLC Q-TOF/HSMS/MS ^E . Journal of Proteome Research, 2013, 12, 692-703.	1.8	152
129	UPLC-Q-TOF/HSMS/MSE-based metabonomics for adenine-induced changes in metabolic profiles of rat faeces and intervention effects of ergosta-4,6,8(14),22-tetraen-3-one. Chemico-Biological Interactions, 2013, 201, 31-38.	1.7	78
130	Renal metabolic profiling of early renal injury and renoprotective effects of Poria cocos epidermis using UPLC Q-TOF/HSMS/MSE. Journal of Pharmaceutical and Biomedical Analysis, 2013, 81-82, 202-209.	1.4	69
131	Metabonomic study of biochemical changes in the rat urine induced by Pinellia ternata (Thunb.) Berit Journal of Pharmaceutical and Biomedical Analysis, 2013, 85, 186-193.	1.4	25
132	Folate-functionalized nanoparticles for controlled ergosta-4,6,8(14),22-tetraen-3-one delivery. International Journal of Pharmaceutics, 2013, 441, 1-8.	2.6	15
133	General toxicity of Pinellia ternata (Thunb.) Berit. in rat: A metabonomic method for profiling of serum metabolic changes. Journal of Ethnopharmacology, 2013, 149, 303-310.	2.0	50
134	Diuretic activity of some fractions of the epidermis of Poria cocos. Journal of Ethnopharmacology, 2013, 150, 1114-1118.	2.0	86
135	Metabolomics in chronic kidney disease. Clinica Chimica Acta, 2013, 422, 59-69.	0.5	199
136	Pharmacokinetics of 2,3,5,4′â€tetrahydroxystilbeneâ€2â€ <scp>O</scp> â€Î²â€ <scp>D</scp> â€glucoside in rat ultraâ€performance <scp>LC</scp> â€quadrupole <scp>TOF</scp> â€ <scp>MS</scp> . Journal of Separation Science, 2013, 36, 863-871.	t using 1.3	37
137	Solvent effects on the absorption and fluorescence spectra of rhaponticin: Experimental and theoretical studies. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2013, 102, 194-199.	2.0	20
138	Cloud-Point Extraction Combined with Liquid Chromatography for the Determination of Ergosterol, a Natural Product with Diuretic Activity, in Rat Plasma, Urine, and Faeces. Journal of Analytical Methods in Chemistry, 2013, 2013, 1-8.	0.7	6
139	Quality Control of Natural Product Medicine and Nutrient Supplements. Journal of Analytical Methods in Chemistry, 2013, 2013, 1-2.	0.7	2
140	Ultra Performance Liquid Chromatography-Based Metabonomic Study of Therapeutic Effect of the Surface Layer of Poria cocos on Adenine-Induced Chronic Kidney Disease Provides New Insight into Anti-Fibrosis Mechanism. PLoS ONE, 2013, 8, e59617.	1.1	105
141	A simple and rapid spectrofluorimetric method for determining the pharmacokinetics and metabolism of rhaponticin in rat plasma, feces and urine using a cerium probe. Luminescence, 2013, 28, 523-529.	1.5	6
142	Aggregationâ€Induced Emission of 1,8â€NaphthalimideCasein Micelle: Investigation by Synchronous Spectrographic Method. Chemistry and Biodiversity, 2013, 10, 1597-1605.	1.0	2
143	PHARMACOKINETICS, BIOAVAILABILITY, AND METABOLISM OF 2,3,5,4â€ ² -TETRAHYDROXYSTILBENE-2-O- <i>Î²</i> -D-GLUCOSIDE IN RATS BY ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY–QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-ULTRAVIOLET DETECTION. Journal of Liquid Chromatography and Related	0.5	6
144	A Sensitive Spectrofluorometric Method for Determination of Ergosta-4,6,8(14),22-Tetraen-3-One in Rat Plasma, Feces, and Urine for Application to Pharmacokinetic Studies Using Cerium(III) as a Probe. Applied Spectroscopy, 2013, 67, 106-111.	1.2	3

#	Article	IF	CITATIONS
145	Enhanced Distribution and Anti-Tumor Activity of Ergosta-4,6,8(14),22-Tetraen-3-One by Polyethylene Glycol Liposomalization. Journal of Nanoscience and Nanotechnology, 2013, 13, 1435-1439.	0.9	8
146	Chemical constituents of surface layer of Poria cocos and their pharmacological properties (â). Zhongguo Zhongyao Zazhi, 2013, , .	0.2	3
147	Chemical composition and antioxidant activities of extracts from Apocyni Veneti Folium. Natural Product Research, 2012, 26, 600-608.	1.0	3
148	Pharmacokinetics, bioavailability and metabolism of rhaponticin in rat plasma by UHPLC–Q-TOF/MS and UHPLC–DAD–MS ⁿ . Bioanalysis, 2012, 4, 713-723.	0.6	24
149	Application of faecal metabonomics on an experimental model of tubulointerstitial fibrosis by ultra performance liquid chromatography/high-sensitivity mass spectrometry with MS ^E data collection technique. Biomarkers, 2012, 17, 721-729.	0.9	73
150	Enhanced Pharmacokinetics and Anti-Tumor Efficacy of PEGylated Liposomal Rhaponticin and Plasma Protein Binding Ability of Rhaponticin. Journal of Nanoscience and Nanotechnology, 2012, 12, 7677-7684.	0.9	12
151	Characterization of the Interaction between 4-(Tetrahydro-2-Furanmethoxy)-N-Octadecyl-1,8-Naphthalimide and Human Serum Albumin by Molecular Spectroscopy and Its Analytical Application. Applied Spectroscopy, 2012, 66, 464-469.	1.2	9
152	A water-soluble, 1,8-naphthalimide based aggregation induced synchronous emission system for selective and sensitive recognition of casein. Analytical Methods, 2012, 4, 4284.	1.3	8
153	Regioselective synthesis and initial evaluation of a folate receptor targeted rhaponticin prodrug. Chinese Chemical Letters, 2012, 23, 1133-1136.	4.8	8
154	Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clinica Chimica Acta, 2012, 413, 642-649.	0.5	149
155	Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: A serum metabonomic study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm. Clinica Chimica Acta, 2012, 413, 1438-1445.	0.5	97
156	Diuretic activity of the ethanol and aqueous extracts of the surface layer of Poria cocos in rat. Journal of Ethnopharmacology, 2012, 144, 775-778.	2.0	73
157	Urinary metabonomics study on the protective effects of ergosta-4,6,8(14),22-tetraen-3-one on chronic renal failure in rats using UPLC Q-TOF/MS and a novel MSE data collection technique. Process Biochemistry, 2012, 47, 1980-1987.	1.8	74
158	Serum metabonomics study of adenine-induced chronic renal failure in rats by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Biomarkers, 2012, 17, 48-55.	0.9	97
159	Ultra performance liquid chromatography coupled with electrospray and atmospheric pressure chemical ionization (ESCi)â€quadrupole timeâ€ofâ€flight mass spectrometry with novel mass spectrometry ^{Elevated Energy} (MS ^{<scp>E</scp>}) data collection technique: Determination and pharmacokinetics, tissue distribution and biliary excretion study of ergone in rat.	1.3	17
160	Sourmat of Separation Science (2012) 39, doi:00.020 Solvent effect on the absorption and fluorescence of ergone: Determination of ground and excited state dipole moments. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2012, 86, 120-123.	2.0	20
161	Studies on the binding of rhaponticin with human serum albumin by molecular spectroscopy, modeling and equilibrium dialysis. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2012, 87, 171-178.	2.0	26
162	Identification of five gelatins by ultra performance liquid chromatography/time-of-flight mass spectrometry (UPLC/Q-TOF-MS) using principal component analysis. Journal of Pharmaceutical and Biomedical Analysis, 2012, 62, 191-195.	1.4	72

#	Article	IF	CITATIONS
163	Interactions between 4-(2-dimethylaminoethyloxy)-N-octadecyl-1,8-naphthalimide and serum albumins: Investigation by spectroscopic approach. Journal of Luminescence, 2012, 132, 879-886.	1.5	22
164	PEG-modified GoldMag nanoparticles (PGMNs) combined with the magnetic field for local drug delivery. Journal of Drug Targeting, 2011, 19, 161-170.	2.1	27
165	Molecular Tectonics of Entangled Metalâ^Organic Frameworks Based on Different Conformational Carboxylates Mixed with a Flexible N,Nâ€2-Type Ligand. Crystal Growth and Design, 2011, 11, 569-574.	1.4	61
166	Ergosta-4,6,8(14),22-tetraen-3-one induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Biochimica Et Biophysica Acta - General Subjects, 2011, 1810, 384-390.	1.1	75
167	Ergosta-4,6,8(14),22-tetraen-3-one isolated from <i>Polyporus umbellatus</i> prevents early renal injury in aristolochic acid-induced nephropathy rats. Journal of Pharmacy and Pharmacology, 2011, 63, 1581-1586.	1.2	53
168	Studies of Interaction between Ergostaâ€4,6,8(14),22â€ŧetraenâ€3â€one (Ergone) and Human Serum Albumin by Molecular Spectroscopy and Modeling. Journal of the Chinese Chemical Society, 2011, 58, 602-610.	^y 0.8	7
169	Crystal and Molecular Structure of Rhaponticin from Rheum hotaoense. Journal of Chemical Crystallography, 2011, 41, 409-414.	0.5	10
170	LC Method for the Determination of Rhaponticin in Rat Plasma, Faeces and Urine for Application to Pharmacokinetic Studies. Chromatographia, 2011, 73, 599-603.	0.7	11
171	Pharmacokinetics of ergosterol in rats using rapid resolution liquid chromatography–atmospheric pressure chemical ionization multi-stage tandem mass spectrometry and rapid resolution liquid chromatography/tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2011. 879. 1945-1953.	1.2	26
172	Synthesis and spectroscopic characterization of 4-butoxyethoxy-N-octadecyl-1,8-naphthalimide as a new fluorescent probe for the determination of proteins. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3798-3804.	1.0	65
173	Simultaneous determination of eight major steroids from <i>Polyporus umbellatus</i> by highâ€performance liquid chromatography coupled with mass spectrometry detections. Biomedical Chromatography, 2010, 24, 222-230.	0.8	29
174	A fast and sensitive HPLC–MS/MS analysis and preliminary pharmacokinetic characterization of ergone in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 29-33.	1.2	23
175	Quantitative HPLC method and pharmacokinetic studies of ergosta-4,6,8(14),22-tetraen-3-one, a natural product with diuretic activity from Polyporus umbellatus. Biomedical Chromatography, 2010, 24, 1120-1124.	0.8	22
176	Rapid resolution liquid chromatography–mass spectrometry and high-performance liquid chromatography-fluorescence detection for metabolism and pharmacokinetic studies of ergosta-4,6,8(14),22-tetraen-3-one. Analytica Chimica Acta, 2010, 675, 199-206.	2.6	28
177	Cytotoxic Steroids from <i>Polyporus umbellatus</i> . Planta Medica, 2010, 76, 1755-1758.	0.7	51
178	1β-hydroxylfriedelin, a new natural pentacylic triterpene from the sclerotia of <i>Polyporus umbellatus</i> . Journal of Chemical Research, 2009, 2009, 699-701.	0.6	17
179	An expeditious HPLC method to distinguish Aconitum kusnezoffii from related species. Fìtoterapìâ, 2009, 80, 333-338.	1.1	35
180	Bioactivity-directed isolation, identification of diuretic compounds from Polyporus umbellatus. Journal of Ethnopharmacology, 2009, 126, 184-187.	2.0	67

#	Article	IF	CITATIONS
181	Qualitative and quantitative analysis of the diuretic component ergone in Polyporus umbellatus by HPLC with fluorescence detection and HPLC-APCI-MS/MS. Die Pharmazie, 2009, 64, 366-70.	0.3	23
182	Recent advances of gut microbiota in chronic kidney disease patients. Exploration of Medicine, 0, , 260-274.	1.5	8